Curcumin Enhances Antimigration of Pentagamavunon-1 by Suppressing MMP-2 and MMP-9 Expression in Triple-Negative (4T1) and Luminal A (T47D) Breast Cancer Cells
Abstract
BACKGROUND: Breast cancer remains the leading cause of cancer death worldwide. Migration and invasion of cancer cells are still crucial stages in the metastasis process, highlighting the urgent need for treatments that target both proliferation and metastatic progression. Curcumin and its synthetic analogue, pentagamavunon (PGV)-1, exhibit antiproliferative effects in breast cancer cells. However, the effects of combining curcumin and PGV-1 on cancer cell migration have not yet been explored. Therefore, this study was conducted to examine the antimigratory effects of curcumin and PGV-1 combination on 4T1 and T47D breast cancer cells.
METHODS: Cytotoxicity effects of curcumin and PGV-1 were examined using an MTT assay to determine their effects on 4T1 and T47D cell viability. The antimigration activity was assessed using a scratch wound healing assay by measuring the closure of artificially created wounds on monolayer cells. Expression of matrix metalloproteinases (MMPs) that play a crucial role in cancer cell migration was analyzed using gelatin zymography to measure their enzymatic activities.
RESULTS: The IC50 of PGV-1 and curcumin were 4.88 μM and 37.62 μM in 4T1 cells and 3.16 μM and 23.15 μM in T47D cells, respectively. Furthermore, combination of PGV-1 and curcumin effectively inhibited 4T1 and T47D cell migration. PGV-1 (0.5–2 μM) demonstrated superior antimigratory activity compared to curcumin (5–20 μM) by suppressing MMP-2 and MMP-9 expression in both cell lines. Significantly, curcumin was shown to synergistically enhance the antimigratory effects of PGV-1, leading to a further decrease in MMP-2 and MMP-9 expression.
CONCLUSION: The combination of PGV-1 and curcumin may provide a promising antimigratory agent, potentially leading to enhanced antimetastatic strategies and more efficacious treatments for triple-negative and luminal breast cancer patients.
KEYWORDS: antimigration, curcumin, luminal breast cancer, MMP-2, MMP-9, pentagamavunon-1, triple-negative breast cancer
Full Text:
PDFReferences
Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer. 2021; 124(1): 13-26, CrossRef.
Botlagunta M, Botlagunta MD, Myneni MB, Lakshmi D, Nayyar A, Gullapalli JS, et al. Classification and diagnostic prediction of breast cancer metastasis on clinical data using machine learning algorithms. Sci Rep. 2023; 13(1): 485, CrossRef.
Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T. Metastatic and triple-negative breast cancer: Challenges and treatment options. Drug Deliv Transl Res. 2018; 8(5): 1483-507, CrossRef.
Batra H, Pawar S, Bahl D. Curcumin in combination with anti-cancer drugs: A nanomedicine review. Pharmacol Res. 2019; 139: 91-105, CrossRef.
Al-Roub A, Akhter N, Al-Rashed F, Wilson A, Alzaid F, Al-Mulla F, et al. TNFα induces matrix metalloproteinase-9 expression in monocytic cells through ACSL1/JNK/ERK/NF-kB signaling pathways. Sci Rep. 2023; 13(1): 14351, CrossRef.
Di Micco R, Santurro L, Gasparri ML, Zuber V, Fiacco E, Gazzetta G, et al. Rare sites of breast cancer metastasis: A review. Transl Cancer Res. 2019; 8(2): S518-52, CrossRef.
Hunter KW, Crawford NPS, Alsarraj J. Mechanisms of metastasis. Breast Cancer Res. 2008; 10(Suppl 1): S2, CrossRef.
Nathanson SD, Detmar M, Padera TP, Yates LR, Welch DR, Beadnell TC, et al. Mechanisms of breast cancer metastasis. Clin Exp Metastasis. 2022; 39(1): 117-37, CrossRef.
Park M, Kim D, Ko S, Kim A, Mo K, Yoon H. Breast cancer metastasis: Mechanisms and therapeutic implications. Int J Mol Sci. 2022; 23(12): 6806, CrossRef.
Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers. 2021; 13(17): 4287, CrossRef.
Nikolov A, Popovski N. Role of gelatinases MMP-2 and MMP-9 in healthy and complicated pregnancy and their future potential as preeclampsia biomarkers. Diagnostics. 2021; 11(3): 480, CrossRef.
Moirangthem A, Bondhopadhyay B, Mukherjee M, Bandyopadhyay A, Mukherjee N, Konar K, et al. Simultaneous knockdown of uPA and MMP9 can reduce breast cancer progression by increasing cell-cell adhesion and modulating EMT genes. Sci Rep. 2016; 6: 21903, CrossRef.
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011; 144(5): 646-74, CrossRef.
Nurrochmad A, Lukitaningsih E, Meiyanto E. Anti cancer activity of rodent tuber (Thyphonium flagelliforme (Lodd.) Blume on human breast cancer T47D cells. Intl J Phytomed. 2011; 3: 138-46, article.
Rahmawati DR, Nurrochmad A, Jenie RI, Meiyanto E. The synergistic cytotoxic effect of pentagamavunon-1 (PGV-1) and curcumin correlates with the cell cycle arrest to induce mitotic catastrophe in 4T1 and T47D breast cancer cells. Indones Biomed J. 2023; 15(5): 318-27, CrossRef.
Hapsari NP, Rahmawati DR, Nugraheni N, Hanifa M, Satria D, Zaitun Hasibuan PA, et al. Africa leaf (Vernonia amygdalina Delille.) DCM extract synergistically supports growth suppression effect of doxorubicin on MCF7 and MCF7/HER2 with different effects on cell cycle progression and apoptosis evidence. J Appl Pharm Sci. 2024; 14(7): 75-81, CrossRef.
Rahmawati DR, Nugraheni N, Hapsari NP, Hanifa M, Prasetyaningrum PW, Kastian RF, et al. Dichloromethane fraction of Vernonia amygdalina Delile synergistically enhances cytotoxicity of doxorubicin on 4T1 triple negative breast cancer cells through apoptosis induction and cell cycle modulation. Indonesian J Pharm. 2024; in Press, CrossRef.
Zufairo SK, Rahmawati DR, Meiyanto E, Susidarti RA. Citrus sinensis peel extract synergistically enhances the cytotoxic effect of chemotherapeutic agents on HepG2 cells. Indones J Cancer Chemoprevent. 2024; 14(3): 151-9, CrossRef.
Putri AP, Rahmawati DR, Rahman FA, Meiyanto E, Ikawati M. Chromolaena odorata L. leaf extract elevates cytotoxicity of doxorubicin on 4T1 breast cancer cells. Indones J Cancer Chemoprevent. 2024; 14(3): 160-70, CrossRef.
Priyangga KTA, Sagita CP, Yuliati L. A narrative review of curcuminoids from various Curcuma species in Indonesia as potential antidiabetic agents. Longhua Chinese Med. 2021; 4(1): 23, CrossRef.
de Campos PS, Matte BF, Diel LF, Jesus LH, Bernardi L, Alves AM, et al. Low doses of Curcuma longa modulates cell migration and cell-cell adhesion. Phyther Res. 2017; 31(9): 1433-40, CrossRef.
Larasati YA, Yoneda-Kato N, Nakamae I, Yokoyama T, Meiyanto E, Kato JY. Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. Sci Rep. 2018; 8(1): 2039, CrossRef.
Bučević Popović V, Karahmet Farhat E, Banjari I, Jeličić Kadić A, Puljak L. Bioavailability of oral curcumin in systematic reviews: A methodological study. Pharmaceuticals. 2024; 17(2): 164, CrossRef.
Park W, Ruhul Amin ARM, Chen ZG, Shin DM. New perspectives of curcumin in cancer prevention. Cancer Prev Res. 2013; 6(5): 387-400, CrossRef.
Sohn SI, Priya A, Balasubramaniam B, Muthuramalingam P, Sivasankar C, Selvaraj A, et al. Biomedical applications and bioavailability of curcumin-an updated overview. Pharmaceutics. 2021; 13(12): 2102, CrossRef.
Murwanti R, Kholifah E, Ari Sudarmanto BS, Hermawan A. Curcumin and its analogue targeting β-catenin and GSK-3β in Wnt signaling pathways: In vitro and in silico study. Res J Pharm Technol. 2020; 13(4): 1715-9, CrossRef.
Ramadhan F, Jamaluddin, Zuhria I, Indriaswati L, Komaratih E. Matrix metalloproteinase-3 down regulation and cell migration inhibition in human pterygium fibroblasts by mitomycin-C, curcumin and fibrin glue. Indones Biomed J. 2022; 14(2): 172-9, CrossRef.
Ikawati M, Utomo RY, Hapsari NP, Meiyanto E, Oka C. Diosmin enhances the anti-migration activity of curcumin analog PGV-1 on colorectal cancer cells. Indones Biomed J. 2024; 16(1): 56-65, CrossRef.
Hosseini F, Ahmadi A, Hassanzade H, Gharedaghi S, Rassouli FB, Jamialahmadi K. Inhibition of melanoma cell migration and invasion by natural coumarin auraptene through regulating EMT markers and reducing MMP-2 and MMP-9 activity. Eur J Pharmacol. 2024; 971: 176517, CrossRef.
Sardjiman SS, Reksohadiprodjo MS, Hakim L, Goot H, Timmerman H. Diphenyl-1, 4-pentadiene-3-ones and cyclic analogues as antioxidative agents. Synthesis and structure-activity relationship. Eur J Med Chem 1997; 32: 625-30, CrossRef.
Lestari B, Nakamae I, Yoneda-Kato N, Morimoto T, Kanaya S, Yokoyama T, et al. Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence. Sci Rep. 2019; 9(1): 14867, CrossRef.
Santoso CF, Rahmawati DR, Nugraheni N, Rahmadhany M. Chemopreventive properties Curcuma heyneana rhizome ethanolic extract on hepatocellular carcinoma cells, JHH-4. Indones J Cancer Chemoprevent. 2024; 15(1): 40-9, CrossRef.
Hansen Ree A, Bjørnland K, Brünner N, Thidemann Johansen H, Boye Pedersen K, Aasen AO, et al. Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells. Clin Exp Metastasis. 1998; 16: 205-15, CrossRef.
Cheng R, Liu YJ, Cui JW, Yang M, Liu XL, Li P, et al. Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells. Oncotarget. 2017; 8(18): 30252-64, CrossRef.
Sun Y, Lu N, Ling Y, Gao Y, Chen Y, Wang L, et al. Oroxylin A suppresses invasion through down-regulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Eur J Pharmacol. 2009; 603(1-3): 22-8, CrossRef.
Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics. 2023; 15(7): 1796, CrossRef.
Fan S, Liao Y, Liu C, Huang Q, Liang H, Ai B, et al. Estrogen promotes tumor metastasis via estrogen receptor beta-mediated regulation of matrix-metalloproteinase-2 in non-small cell lung cancer. Oncotarget. 2017; 8(34): 56443-59, CrossRef.
Tester AM, Ruangpanit N, Anderson RL, Thompson EW. MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits. Clin Exp Metastasis. 2000; 18(7): 553-60, CrossRef.
Köhrmann A, Kammerer U, Kapp M, Dietl J, Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer. 2009; 9: 188., CrossRef.
Meiyanto E, Putri H, Larasati YA, Utomo RY, Jenie RI, Ikawati M, et al. Anti-proliferative and anti-metastatic potential of curcumin analogue, pentagamavunon-1 (PGV-1), toward highly metastatic breast cancer cells in correlation with ROS generation. J Cardiovasc Thorac Res. 2019; 9(3): 445-52, CrossRef.
Rifai FNP, Zulfin UM, Tafrihani AS, Ikawati M, Meiyanto E. Hesperidin enhanced the antimigratory activity and senescence-mediated G2/M arrest effect of PGV-1 against T47D luminal breast cancer cells. Indones J Pharm. 2024; 35(1): 126-37, CrossRef.
Karroum A, Mirshahi P, Faussat AM, Therwath A, Mirshahi M, Hatmi M. Tubular network formation by adriamycin-resistant MCF-7 breast cancer cells is closely linked to MMP-9 and VEGFR-2/VEGFR-3 over-expressions. Eur J Pharmacol. 2012; 685(1-3): 1-7, CrossRef.
Meiyanto E, Melannisa R, Da'i M. PGV-1 menurunkan ekspresi faktor angiogenesis (VEGF dan COX-2) pada sel T47D terinduksi estrogen. Indonesian J Pharm. 2006; 17(1): 1-6.
DOI: https://doi.org/10.18585/inabj.v17i1.3431
Copyright (c) 2025 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
